Literature DB >> 12086860

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Keiichi Kondo1, Jeff Klco, Eijiro Nakamura, Mirna Lechpammer, William G Kaelin.   

Abstract

Inactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of hereditary (VHL Disease-associated) and sporadic clear cell carcinoma of the kidney. The VHL gene product, pVHL, targets the heterodimeric transcription factor HIF for polyubiquitination, and restoration of pVHL function in VHL(-/-) renal carcinoma cells suppresses their ability to form tumors in nude mice. Here we show that tumor suppression by pVHL can be overridden by a HIF variant that escapes pVHL control. These studies prove that HIF is a critical downstream target of pVHL and establish that activation of HIF target genes can promote tumorigenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086860     DOI: 10.1016/s1535-6108(02)00043-0

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  304 in total

1.  A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Authors:  Natsuko Suwaki; Elsa Vanhecke; Katelyn M Atkins; Manuela Graf; Katherine Swabey; Paul Huang; Peter Schraml; Holger Moch; Amy Mulick Cassidy; Daniel Brewer; Bissan Al-Lazikani; Paul Workman; Johann De-Bono; Stan B Kaye; James Larkin; Martin E Gore; Charles L Sawyers; Peter Nelson; Tomasz M Beer; Hao Geng; Lina Gao; David Z Qian; Joshi J Alumkal; Gary Thomas; George V Thomas
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

Review 2.  Renal cancer: oxygen meets metabolism.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

Review 3.  HIF hydroxylation and the mammalian oxygen-sensing pathway.

Authors:  Michal Safran; William G Kaelin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 4.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

5.  Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation.

Authors:  Hongxia Z Imtiyaz; Emily P Williams; Michele M Hickey; Shetal A Patel; Amy C Durham; Li-Jun Yuan; Rachel Hammond; Phyllis A Gimotty; Brian Keith; M Celeste Simon
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

6.  Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host.

Authors:  Tetsuhiro Tanaka; Junna Yamaguchi; Kumi Shoji; Masaomi Nangaku
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

7.  DNMT3a epigenetic program regulates the HIF-2α oxygen-sensing pathway and the cellular response to hypoxia.

Authors:  Gabriel Lachance; James Uniacke; Timothy E Audas; Chet E Holterman; Aleksandra Franovic; Josianne Payette; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-09       Impact factor: 11.205

8.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

10.  Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.

Authors:  Chun-Xiong Zhao; Chun-Li Luo; Xiao-Hou Wu
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.